Drug intelligence / Profile preview

etoposide + cytarabine + mercaptopurine

Development stage: Unknown
Lead developer: Children's Oncology Group
Modality: Small Molecules
Administration: Intravenous, Oral, Intrathecal

Overview

A chemotherapy combination regimen consisting of etoposide, cytarabine, and mercaptopurine. This combination has been studied in the treatment of various types of leukemia, particularly acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). Clinical trials have investigated whether replacing standard regimens with this combination during consolidation or delayed intensification phases of treatment would improve outcomes for patients with leukemia.

Targets

HPRT1 (Hypoxanthine-guanine phosphoribosyltransferase)DNA polymerase familyPPAT (Amidophosphoribosyltransferase)IMPDH (Inosine-5'-monophosphate dehydrogenase 1)TOP2A (DNA topoisomerase II)

Beyond the preview

Go deeper on etoposide + cytarabine + mercaptopurine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on etoposide + cytarabine + mercaptopurine.

Explore the full profile